98LBA Late Breaking - Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors

Subjects

Subjects :

*PANITUMUMAB
*THERAPEUTIC use of monoclonal antibodies
*CONFERENCES & conventions
*TUMORS
*EPIDERMAL growth factor receptors

Details

Language :

English

ISSN :

09598049

Volume :

138

Database :

Academic Search Index

Journal :

European Journal of Cancer

Publication Type :

Academic Journal

Accession number :

148120195

Full Text :

https://doi.org/10.1016/S0959-8049(20)31083-2